C hronic hepatitis C virus (HCV) is a highly burdensome public health problem in Canada, causing more years of life lost than any other infectious disease in the country. [1] [2] [3] A recent modelling study suggested that about 252 000 Canadians (uncertainty interval: 178 000-315 000 Can adians) were chronically infected in 2013. The birth cohort of has the highest prevalence of chronic HCV infection, yet it is estimated that up to 70% of this group have not been tested for HCV. 4 Although the overall prevalence of chronic hepatitis C is declin ing, complications of the disease are increasing because of aging of the infected population and progression of liver fibrosis. [1] [2] [3] Mod elling data suggest that if nothing is done to change the current situation, cases of decompensated cirrhosis, hepatocellular car cinoma and liverrelated mortality will increase by 80%, 205% and 160%, respectively, by 2035 compared with 2013 levels. 2 The primary objective of antiHCV therapy is complete eradica tion of the virus, termed a sustained virologic response, which is defined as absence of viremia 12 weeks after completion of ther apy. 5 Once achieved, sustained virologic response is considered a true cure of the viral infection, as late relapses are very uncom mon. 6, 7 Sustained virologic response is associated with longterm health benefits that include improved quality of life 8, 9 and liver his tology, 10, 11 and reduced incidence of hepatocellular carcinoma, Study of the Liver appointed two cochairs of the guideline panel (H.S. and J.F.). The cochairs selected six other members of the guideline panel based on their expertise in specific areas of HCV management, including hepatology, infectious disease, public health, clinical care, research and epidemiology.
Guideline development
Two panel members were assigned to each guideline section (epi demiology, screening, treatment indications and contraindica tions, pretreatment assessment, antiviral therapy [genotype 1 (G1) naive, G1 experienced, G2, G3, G4, G5/6], resistance, special popu lations [chronic kidney disease, decompensated cirrhosis, liver transplant, people who use drugs, acute HCV, directacting anti viral failures]), one to serve as the primary section author and the other as a secondary reviewer. A focused literature search for both published and unpublished literature was undertaken to update the evidence base used in the 2015 guideline. In brief, the litera ture search was conducted in MEDLINE (Jan. 15, 2015 to Oct. 31, 2016) , using the following search terms: hepatitis C, hepatitis and treatment. Englishlanguage articles were included. There were no other exclusion criteria. The literature search was updated (Oct. 17, 2017 ) before publication to capture any recent studies. Section authors screened the search results for studies rele vant to their section topics. Potentially relevant citations were retrieved and reviewed in full text, as well as unpublished abstracts presented at international hepatology and infectious disease conferences. Abstract authors were contacted to provide additional details as required. After review of the relevant 2015 guideline recommendations, the primary author for each section drafted the new recommendations and graded the supporting evidence, using the rating scheme from the American College of Cardiology Foundation and the American Heart Association prac tice guideline, 18, 19 as used in similar practice guidelines by the Canadian Association for the Study of the Liver. 20 Recommenda tions were assigned a class (reflecting benefit versus risk) and level of evidence (assessing strength of certainty) (Box 1).
The secondary author reviewed recommendations and sup porting evidence for each section, and any disagreements were resolved by consensus. In most cases, the text of the 2015 guide line was modified for this update. The entire guideline panel then reviewed all recommendations and supporting evidence through dedicated recorded teleconferences. For a recommendation to be included in the guideline, consensus on the recommendation, including grading (class of recommendation, level of evidence), was required and defined as a twothirds majority. Voting was done electronically by email for recommendations for which there was not consensus.
Stakeholder input
Although the guideline panel did not include any patient repre sentatives, a final draft version of the guideline was circulated by email for comment to the entire membership of the Canadian Association for the Study of the Liver and community organiza tions that represented patients. Substantive comments were received from nine association members, including physicians and allied health workers. The guideline panel reviewed all com ments received and made revisions to the guideline after discus sion; a twothirds majority agreement was required for a change to be incorporated. The executive of the Canadian Association for the Study of the Liver reviewed and approved this final version.
Management of competing interests
Members of the guideline panel have financial relationships with pharmaceutical companies related to HCV therapeutics. All members signed a commitment and competing interest state ment at the outset of guideline development. Individuals with relevant disclosures were not excluded from voting on recom mendations. However, in order to manage competing interests, the final guideline was vetted by the Canadian Association for the Study of the Liver membership, and specifically by the asso ciation's executive, to evaluate the presence of commercial bias. No funding, direct or in kind, was provided to the guideline panel for this work.
Recommendations
This abridged document summarizes key recommendations for practice and supporting evidence, which is expanded upon in the full guideline (available in Appendix 1, www.cmaj.ca/lookup/ suppl/doi:10.1503/cmaj.170453//DC1).
Screening and linkage to care
To increase the identification of the large proportion of persons living with undiagnosed HCV, we recommend that screening be both Box 1: Grading system for recommendations 20 
Classification
Description
Class of evidence

Class 1
Conditions for which there is evidence or general agreement that a given diagnostic evaluation procedure or treatment is beneficial, useful and effective.
Class 2
Conditions for which there is conflicting evidence or a divergence of opinion about the usefulness or efficacy of a diagnostic evaluation, procedure or treatment.
Class 2a
Weight of evidence or opinion is in favour of usefulness or efficacy.
Class 2b
Usefulness or efficacy is less well established by evidence or opinion.
Class 3
Conditions for which there is evidence or general agreement that a diagnostic evaluation, procedure or treatment is not useful or effective and in some cases may be harmful. Despite a diagnosis of chronic hepatitis C, many patients are never seen by HCV experts, leading to low rates of treatment uptake and screening for complications. 29 Training primary care providers, addiction specialists, nurses and nurse practitioners to provide HCV care, as well as using telemedicine approaches (e.g., Project ECHO) to comanage patients, can lead to delivery of highquality HCV treatment with outcomes similar to those achieved in academic centres. 30, 31 Expansion of nonspecialist HCV care will be required in Canada to ensure that all infected individuals receive appropriate care.
Grade of evidence
Treatment
All patients with chronic HCV infection should be considered candidates for antiviral therapy (class of recommendation: 1; level of evidence: A).
The landscape of antiviral treatment for hepatitis C is chang ing rapidly. With the markedly improved efficacy and safety of current therapy based on directacting antiviral agents and the welldocumented benefits of achieving sustained virologic response, there is no longer any medical justification to restrict therapy, except in individuals with severe comorbidities and short life expectancy unrelated to HCV infection. As such, all indi viduals with chronic HCV infection should be considered candi dates for antiviral therapy. 33 and those with extrahepatic manifestations of HCV infection. 34 Patients with mild fibrosis (F0-F2) should also be considered for treatment. Viral eradication in this group improves health related quality of life 8, 9 and may prevent incident infections in those at risk of infecting others (e.g., people engaged in high risk activities). 35 Notably, a careful review by the Canadian Agency for Drugs and Technologies in Health (CADTH) showed that treatment of HCV with interferonfree directacting antiviral agent-based therapy is costeffective at all stages of fibrosis. 36 Recent negotiated price reductions should make treatment more costeffective (through the panCanadian Pharmaceutical Alliance). Although some regions in Canada continue to limit access to treatment to those with hepatic fibrosis, there is no medical or epidemiological evi dence to support restrictions based on fibrosis stage. 32, [37] [38] [39] [40] Price reductions have led to removal of restrictions in many jurisdictions.
Pretreatment evaluation
Initial evaluation should include questions about risk factors for viral acquisition to determine risks for transmission and estimate duration of infection, signs and symptoms of advanced liver dis ease or extrahepatic manifestations of chronic hepatitis C (e.g., rash, renal disease) and the presence of cofactors that may accelerate disease progression (e.g., alcohol, obesity, coinfec tions). Necessary laboratory testing includes virologic tests to confirm and characterize the infection (HCV RNA viral load, HCV genotype), liver biochemistry and function, abdominal ultra sound, an assessment of fibrosis stage and tests to rule out coin fections, such as hepatitis B virus and HIV (see Table 1 and Sup plemental Table 2b in Appendix 1 for more information).
Determination of HCV RNA, genotype and subtype (i.e., 1a v. 1b) is helpful in the management of patients with chronic HCV infection (class of recommendation: 1; level of evidence: A).
Documentation of viremia (detectable HCV RNA) is required to confirm active HCV infection. Some treatment regimens vary, depending on the level of HCV RNA; however, for most regimens, the HCV RNA level does not influence therapeutic decision making. 41 New regimens are effective against all HCV genotypes, and thus genotyping is not absolutely required before therapy if a pangenotypic regimen is used, particularly in patients who do not have cirrhosis. [42] [43] [44] [45] [46] However, many regimens are genotype and/or subtypespecific, and even with pangenotypic regimens, efficacy varies by genotype, which may be relevant for patients and providers to know before starting therapy. 43, 46 As such, geno typing before starting therapy is still recommended.
Liver fibrosis assessment to identify or exclude advanced fibrosis or cirrhosis is essential to the management of patients with chronic HCV infection (class of recommendation: 1; level of evidence: A).
An assessment of liver fibrosis is essential in all infected individuals. Identifying patients with cirrhosis is particularly important because of their increased risk of hepatic complica tions, lower treatment response and requirement for hepato cellular carcinoma surveillance, even after achievement of sus tained virologic response. 12, 47, 48 In those without overt evidence of cirrhosis on history or exam (e.g., ascites, encephalopathy) or routine tests (e.g., nodular shrunken liver or splenomegaly on ultrasound), an additional dedicated fibrosis assessment is required. Notably, absence of clinical signs or symptoms and even normal radiological findings do not adequately rule out cirrhosis. 21 Numerous noninvasive alternatives to liver biopsy have been developed, 49 [52] [53] [54] [55] ) and other imagingbased tools. These tests are highly accurate for ruling out cirrhosis, the most important and clinically relevant issue. 56 However, practitioners should be aware of the caveats associated with noninvasive approaches to fibrosis staging to allow for correct interpretation.
Direct-acting antiviral agents Given the efficacy and markedly improved safety and tolerability of interferon-free direct-acting antiviral agent regimens, regimens containing pegylated interferon-α are no longer recommended for patients with HCV infection (class of recommendation 3; level of evidence: A).
Multiple steps in the HCV life cycle have proven attractive tar gets for novel pharmacologic therapies (Appendix 1, Supplemen tal Figure 1 ). Agents that target the nonstructural 3/4A (NS3/4A) serine protease (previr), the NS5B RNAdependent RNA poly merase (buvir) and the NS5A protein (asvir) have been devel oped and approved for clinical use. 57 Although initial approvals of directacting antiviral agents involved regimens administered in combination with pegylated interferonα, approvals since 2014 have been exclusively for interferonfree treatment regi mens. Given the markedly improved efficacy, tolerability and safety of regimens that combine various directacting antiviral agents compared with regimens containing interferon, all patients would benefit from interferonfree therapy. 42, 46, 58, 59 Therefore, interferonfree regimens are recommended as first line therapy for all indications.
Different classes of directacting antiviral agents have been combined to overcome drug resistance. However, substitutions in the viral sequence that are associated with resistance to anti virals (resistanceassociated substitutions), particularly to NS5A inhibitors, may be present in some patients even before they receive therapy. For patients with genotype 1a and genotype 3 infections, the presence of baseline resistance may affect treat ment choices, and we suggest testing in certain circumstances (see Appendix 1 for more details). For patients with other geno types, the importance of resistanceassociated substitutions is less clear and we do not recommend baseline testing.
Before beginning any directacting antiviral agent, potential drug-drug interactions must be considered, including those attributable to prescription and overthecounter and herbal preparations. We suggest referring to an online updated data base of drug-drug interactions before starting therapy (e.g., www.hepdruginteractions.org).
Treatment regimens
The suggested workup before beginning HCV therapy is out lined in Table 1 , with approved directacting antiviral agents HCV regimens in Canada listed in Table 2. Table 3 outlines treatment recommendations for people who have never received previous HCV treatment (treatmentnaive) without cir rhosis. Regimens are recommended by HCV genotype, with the duration in weeks indicated. Treatment recommendations for people who have never received HCV treatment (treatment naive) with compensated cirrhosis are similarly outlined in Table 4 . Recommendations for people who have been treated previously and for those with specific comorbidities (i.e., chronic kidney disease, decompensated cirrhosis, postliver transplantation, hepatitis B coinfection, injection drug use and others) are available in Appendix 1.
For all recommendations, the primary criteria for selecting a recommended regimen were antiviral efficacy (rate of sustained virologic response) and safety in phase III trials. Although some regimens may require longer duration of therapy, have more drug interactions, additional adverse effects or a higher pill bur den, or require the use of ribavirin, such regimens were still listed as "recommended" if robust data demonstrated high efficacy and safety. For regimens in which resistance testing is recom mended, strategies for patients with and without detectable resistanceassociated substitutions are listed.
For each HCV genotype, multiple approved regimens are available. The comprehensive efficacy and safety data support ing the recommendation of each regimen for each population are provided in Appendix 1. • To select appropriate regimen, and consideration for addition of ribavirin. Genotype 1: Genotype 1 is the most prevalent HCV genotype in Canada and most patients are infected with either genotype 1a or 1b. 60 Subtyping is important because some regimens are more effective against genotype 1b than 1a. 61 Treatment recommenda tions for treatmentnaive patients without cirrhosis (Table 3) and with compensated cirrhosis (Table 4) are listed by genotype and subtype. Baseline resistance testing is recommended in clinical situations for which outcomes differ and alternative treatment strategies exist.
Genotype 2:
Although high sustained virologic response rates were achieved with interferonbased therapy for genotype 2 infection, the improved tolerability, shorter course and improved sustained virologic response rates with interferonfree regimens justify their use. 43, 44, 62 Treatment recommendations are pre sented for patients who are treatmentnaive without cirrhosis (Table 3) or with compensated cirrhosis (Table 4) .
Genotype 3:
Genotype 3 infection is associated with more aggres sive natural history, faster progression to cirrhosis and higher rates of hepatocellular carcinoma than other HCV genotypes. 63 Patients with HCV genotype 3 and cirrhosis have lower sustained virologic response rates than other populations treated with directacting antiviral agents. 43 Treatment recommendations are presented for patients who are treatmentnaive without cirrhosis (Table 3) or with compensated cirrhosis (Table 4) .
Genotypes 4, 5, 6:
Genotype 4 is very diverse, with multiple sub types; however, to date no clear difference in response has been observed by subtype. Studies of genotype 5 and genotype 6 are limited because of the low prevalence of these patients with these HCV genotypes in Europe and North America. Treatment recommendations are presented for patients who are treatment naive without cirrhosis (Table 3) or with compensated cirrhosis (Table 4) .
Decompensated cirrhosis and post-liver transplantation:
Decompensated cirrhosis refers to present or history of ascites, esophageal variceal hemorrhage, jaundice or hepatic encepha lopathy. Patients with decompensated cirrhosis have a high risk of morbidity and shortterm liverrelated mortality and thus should be treated in centres experienced in managing endstage liver disease. Notably, all protease inhibitors (grazoprevir, gleca previr, paritaprevir, voxilaprevir, simeprevir) are contraindicated in patients with decompensated cirrhosis, because these drugs are hepatically metabolized and may accumulate to very high and toxic levels in patients with impaired hepatic function. 64 Although regimens that are not based on protease inhibitors appear safe, instances of hepatotoxicity or worsening decom pensation during treatment have been reported. 65 The benefits of antiviral therapy must be carefully weighed against the risks of ontreatment complications and the prospect of limited improvement with sustained virologic response in patients with decompensated cirrhosis. No firm criteria have been established to identify patients who should defer treatment until after trans plantation. However, we suggest that patients with Model for Endstage Liver Disease (MELD) scores above 15 to 18 may bene fit from deferral of therapy. [66] [67] [68] [69] [70] Patients with decompensated cir rhosis should be evaluated in centres that have experience with endstage liver disease because of the risk of worsening decom pensation during therapy. Specific recommendations for treat ment of decompensated cirrhosis are presented in Appendix 1. Results of treatment after liver transplantation are similar to those in the nontransplant setting (Appendix 1). However, drugdrug interactions must be carefully considered in all patients. For patients without cirrhosis who achieve sustained viro logic response, no specific followup is required. Patients will remain antiHCV antibodypositive for life, but are not protected from reinfection. 71 The risk of late relapse is extremely low 72, 73 and repeat HCV RNA testing is warranted only in those with unexplained alanine aminotransferase elevation or with on going risk exposures (e.g., people who inject drugs), in whom annual HCV RNA testing should be considered. Individuals who are reinfected should be managed in the same way as anyone with primary HCV, with a continued strong emphasis on harm reduction practices.
Posttreatment follow-up
74
Patients who achieve sustained virologic response and have cirrhosis require ongoing screening for hepatocellular carcinoma indefinitely (class of recommendation: 1; level of evidence: B).
For patients who have cirrhosis before the start of therapy, ongoing followup is required. Surveillance for hepatocellular carcinoma with biannual ultrasound should be continued indefi nitely after sustained virologic response is achieved, even if non invasive tests no longer suggest the presence of cirrhosis. [75] [76] [77] [78] [79] For those with a treated hepatocellular carcinoma before sustained virologic response, close surveillance is required after HCV treat ment, with some reports suggesting an increased risk of recur rence of hepatocellular carcinoma after viral clearance.
80,81
Patients who do not achieve sustained virologic response should be considered for retreatment with a salvage regimen (class of recommendation: 1; level of evidence: A).
For patients who do not achieve sustained virologic response, issues such as adherence and drug-drug interactions should be discussed and retreatment should be considered. Salvage regi mens have recently been approved that have high efficacy and similar safety to other directacting antiviral agent regimens. The fixeddose combination singletablet regimen of sofosbuvir/ velpatasvir/voxilaprevir for 12 weeks is effective against all HCV genotypes with sustained virologic response rates above 95% in patients who did not achieve sustained virologic response after a course of firstline antiviral therapy based on directacting antiviral agents. 82 Other salvage regimens, including the combination of glecaprevir/pibrentasvir, have been less well studied for retreat ment. 83 Details about retreatment are included in Appendix 1.
Implementation
This synopsis and the full version of the guideline (Appendix 1) is posted on the Canadian Association for the Study of the Liver web site (www.hepatology.ca/). In addition, a custom searchable web site is being developed so practitioners can navigate directly to the patient profile of interest. This guideline will be presented to policy makers for integration into Canadian treatment funding models. The impact of these guidelines on resource utilization is unknown. However, there is strong evidence demonstrating the costeffectiveness of hepatitis C treatment for all patient sub groups at all levels of fibrosis. 25, 84, 85 Increased screening efforts and treatment uptake will be required to meet the World Health Organization targets for elimination of HCV as a public health problem by 2030. This document will be updated annually and revised versions of recommendations will be placed on the Canadian Association for the Study of the Liver website immediately.
Other guidelines
The treatment recommendations in this guideline update are markedly changed from the previous Canadian Association for the Study of the Liver treatment guidelines because of multiple advances in the field since their publication, including the devel opment of pangenotypic regimens, retreatment options after nonresponse to directacting antiviral agents and treatment options for populations with substantial medical comorbidities. 16 The current recommendations are very similar to those of other recent guidelines from national and international societies, including the European Association for the Study of the Liver 86 and the American Association for the Study of Liver Disease and Infectious Disease Society of America. 87 The notable differences from these other societies' recom mendations are greater use of resistance testing to guide therapy in our guideline and support for a broader list of recommended therapies in our guideline for some populations. The rationale for these differences is detailed in Appendix 1.
Briefly, new data have emerged to support the use of resis tance testing for certain regimens and certain populations, and testing is readily available in Canada. The guideline panel chose to recommend regimens equally where the efficacy and safety data were similar and where they were supported by highquality evidence without strong consideration of factors that may influ ence the choice of therapy for an individual patient (e.g., pill bur den, drug interactions), but that do not affect overall efficacy or safety of the regimen. Importantly, regimenspecific factors may have a major influence for individuals considering therapy and should be discussed thoroughly by practitioners to help choose the preferred treatment option for a given individual.
The Canadian Task Force for Preventive Health recently pub lished recommendations against screening individuals who are not at high risk of HCV infection. 88 They did not recommend screening the Baby Boomer birth cohort . The guideline panel strongly disagreed with the task force recom mendations and unanimously agreed that the current evidence supports onetime screening of the baby boomer birth cohort in Canada, which is in line with recommendations from other countries for birth cohort screening, most notably the United States 89 and France. 90 The rationale for the difference in screen ing recommendations is explained in greater detail in Appendix 1. Briefly, the panel felt that the task force overvalued the harms of screening, particularly the costs of therapy; undervalued the benefits of curative treatment; relied on outdated data on the costs of HCV therapy and HCV prevalence in Canada; and largely disregarded modelling and costeffectiveness data sup porting screening. We have advocated for screening of the baby boomer cohort for the following reasons: recent data show that the HCV prevalence is highest among the baby boomer birth cohort (1.55%), accounting for an estimated 62.7% of all HCV infections in Canada, and the burden of liver disease is expected to increase markedly in this group; 1,91 best estimates suggest that HCV infection remains undiagnosed in 45%-70% of Canadians infected with HCV, 4, 92 indicating that the long standing policy of screening based on risk factors has been unsuccessful. Moreover, the panCanadian Pharmaceutical Alli ance has recently negotiated markedly lower prices for HCV therapy, leading to broader access for those who have received a diagnosis of HCV infection, making a screenandtreat strat egy even more costeffective than previous estimates 25, 93 and overcoming the concern of the task force that patients will be diagnosed without having access to therapy.
Gaps in knowledge
Despite substantial advances between 2010 and 2017 in efficacy, safety and tolerability of treatment, many gaps in knowledge remain. We are unable to cure every infected patient, and we cur rently have limited treatment options for patients with decom pensated cirrhosis, particularly those who have failed an alloral regimen. These patients represent the minority of individuals with HCV infection.
In the coming years, the major challenge of HCV management will not be treatment, but rather prevention, screening and link age to care. Although many novel models of care have been developed, the optimal strategies, particularly to reach vulnera ble populations, are not clear and must be a major research priority.
The efficacy, safety and simplicity of new HCV regimens mean that therapy no longer must be provided in specialty clinics, with recent data showing high efficacy and improved patient satisfac tion when HCV is treated in primary care. 31 To reach all infected Canadians, expansion of the pool of those providing treatment will need to be a major priority, particularly among primary care providers for populations with a high burden of HCV, such as those born in countries with high prevalence of HCV infection, Indigenous populations and those in addiction services, prisons and other highprevalence settings.
Beyond treatment, addressing HCV in Canada will require coordination of services to address harm reduction and many of the social determinants of health that have an impact on the bur den and course of HCVrelated disease. The development of a coordinated National Action Plan to address HCV, as recom mended by the World Health Organization, should be a priority to ensure that Canada is on track to meet the HCV elimination targets by 2030. 94 
Conclusion
The landscape for HCV treatment continues to change at a rapid pace. This guideline provides updated evidencebased recom mendations for the treatment of patients with HCV infection.
